The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I and pharmacokinetic study of farletuzumab in solid tumors.
Yasutsuna Sasaki
Consultant or Advisory Role - Kohwa; Taiho Pharmaceutical; Takeda
Honoraria - Chugai Pharma; Daiichi Sankyo; Sanofi
Research Funding - Sanofi ; Taiho Pharmaceutical; Yakult Honsha
Keisuke Miwa
No relevant relationships to disclose
Keishi Yamashita
No relevant relationships to disclose
Keiichi Fujiwara
No relevant relationships to disclose
Noriyuki Katsumata
No relevant relationships to disclose
Yasuhiro Fujiwara
No relevant relationships to disclose
Masayuki Namiki
Employment or Leadership Position - Eisai
Nozomu Koyanagi
Employment or Leadership Position - Eisai
Stock Ownership - Eisai